Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Research in Brief1422
EASL Congress 2024494
GORD: pain, PPIs, and preciseness457
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma417
Research in Brief416
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design391
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11371
Lucky: Learning to Live Again307
Viral hepatitis: time for action292
The changing prevalence of functional constipation: why words matter286
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply267
Treatment withdrawal in Crohn's disease: slowly becoming clearer252
Immune checkpoint inhibitors in colorectal cancer: dream and reality246
Trends in alcohol-specific deaths in the UK and industry responses232
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension206
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship205
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study203
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement202
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30200
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled199
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic197
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial196
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study196
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial192
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial173
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium166
Global multi-stakeholder endorsement of the MAFLD definition158
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t156
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives148
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis147
ACG 2024140
Rare cause of dysphagia in a young woman138
Water and sanitation for all136
Bringing organ preservation closer for selected patients with rectal cancer130
The potential of ctDNA in locoregional therapies for colorectal cancer128
Addressing the rise of early-onset colorectal cancer125
Management of portal vein thrombosis in cirrhosis122
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis120
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply119
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere117
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)111
All roads lead to the gut–brain microbiome network110
Availability of point-of-care HBV tests in resource-limited settings110
Local and systemic therapy in liver cancer: the quest for synergy110
Idiopathic gastroparesis consensus misses the patient's voice105
Research in Brief105
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply104
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47102
Long-term VEDOKIDS results: implications for practice and research100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study99
Resmetirom for NASH: balancing promise and prudence98
Uptick of food allergies in recent years—real or epiphenomenon?97
Has the time come for a systematic top-down approach in Crohn's disease?97
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada94
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial94
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study94
Sex and gender in inflammatory bowel disease outcomes and research93
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial92
Practicalities accessing precision medicine in biliary tract cancer91
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study91
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review91
Management of malignant bowel obstruction – Authors' reply90
Britta Siegmund: answering the big questions in IBD90
Research in Brief89
Robotic versus laparoscopic surgery for middle and low rectal cancer88
The Year My Life Went Down the Toilet86
Lifting the minority tax in gastroenterology and hepatology85
Managing inflammatory bowel disease: what to do when the best is unaffordable?80
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist79
Hypovolaemic phlebotomy for hepatic resection78
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations77
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines77
Dangerous Medicine76
Research in Brief76
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED76
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities75
0.031630039215088